Market Research Reports

  The hematological malignancies emerging therapeutics market growth has been primarily attributed to major drivers in this market, such as growing prevalence of hematological malignancies, favorable regulatory environment, and increase in adoption of precision medicine in the field of hematological malignancies. However, there are significant challenges restraining the market growth. These challenges include the high cost hindering the adoption rate, unfavorable reimbursement scenario, and safety concerns pertaining to severe adverse effects. The hematological malignancies emerging therapeutics market report provides a holistic view of the market in terms of various factors influencing it, including reported clinical findings, financing and partnership opportunities, expected market, and current clinical landscape. The global  hematological malignancies emerging therapeutics market  analysis by BIS Research projects the industry to grow at a significant CAGR of 14.20% du...

  The increasing interest of the pharmaceutical industry in cellular immunotherapy potential has been a catalyst for the progress in the global NK cell therapeutics market. The pharmaceutical industry is currently dominated by other immunotherapies such as CAR T-cell therapies, checkpoint inhibitors, and cytokines. However, the proportion of natural killer (NK) cell therapeutics is anticipated to increase given the ability to fulfill unmet medical needs, overcome limitations associated with existing immunotherapies, and address complex, challenging targets. The global  Natural Killer (NK) cell therapeutics market  is expected to reach $5,676.1 million in 2032 from $297.2 million in 2024 at a CAGR of 44.59% during the forecast period 2024-2032. The growth in the global NK cell therapeutics market is expected to be driven by the rising in the number of clinical trials and the increasing incidence and prevalence of cancer cases. Impact of COVID-19 Due to the pandemic, g...

  The global minimal residual disease (MRD) testing market is expected to witness massive growth owing to the high demand for the sensitivity of assays, particularly witnessed in the U.S. With an increasing number of companies attempting to establish synergies in order to enter the market and an increasing number of products acquiring approvals from regulatory bodies; this market will witness tremendous dynamicity. According to the optimistic approach, the market is expected to grow at a CAGR of 17.61% during the forecast period, 2020-2025. Factors considered include high adoption among patients for existing, approved MRD tests, as well as a high rate of return to testing normalcy after the pandemic. In addition, other factors such as the optimum influence of coverage decision and high physician driven MRD testing for patients have also been considered. According to the realistic approach, the market is expected to grow at a CAGR of 15.64% during the forecast period, 2020-2025. Thi...

  The completion of human genome sequencing and the elucidation of the molecular pathways that are critical in the disease molecule interaction have offered an unprecedented opportunity and growth for the development of nucleic acid-based therapeutics. However, to keep with the manufacturing and development of such therapies, the pharmaceutical companies have established partnerships with the contract development and manufacturing company (CDMO) which are the viable alternatives to the in-house development of the drugs. Moreover, the success of the respective business model has also led these CDMOs to become an integral part of such pharmaceutical companies’ value chain. The increasing willingness to outsource drug development to the CDMOs, and the rising need for pharmaceuticals have resulted in the expansion of the global market for nucleic acid therapeutics CDMO. The global  nucleic acid therapeutics CDMO market  is expected to reach $4,463.7 Million by 2030, with a CA...

  Today, digital biomarkers are frequently used for diagnosis and follow-up within therapy. They are objective, quantitative aspects of biological processes that are linked to medical indications, symptoms, surrogate endpoints, and clinical endpoints. There are multiple undergoing studies on how heterogeneous data may be accessible to deduce equivalents to conventional biomarkers when it comes to digital health and the use of smart devices that enable pervasive sensing of surrounding factors such as vital signs. Digital biomarkers have multiple applications across the healthcare industry, and an increasing adoption rate has been observed over the past few years. During the COVID-19 pandemic, technological advancements such as the integration of software and artificial intelligence (AI) in wearable devices, rising adoption of mHealth applications, and growing interest in telemedicine and remote patient monitoring systems have all contributed to the market growth for digital biomarke...

  Biomaterial is referred to any substance which is engineered to become biocompatible for its interaction with the biological systems. Biomaterials can be categorized as synthetic and natural. The synthetic materials consist of metals, polymers and ceramics, whereas natural biomaterials are derived from natural sources such as animal tissues or are engineered in the laboratory. Some tissues are harvested from animal sources such as cows or pigs. The interaction of these biomaterials with the human body aids in the treatment, augmentation, repairing or replacement of a tissue function of the body. The global  biomaterials market  was valued at $122.92 billion in 2020 and is expected to reach $725.88 billion by 2031, growing at a CAGR of 17.98% between 2021 and 2031. The biomaterials market is driven by a number of factors such as superior properties of biomaterials, increasing funds/aids by the government for research purposes, increasing wound healing therapies plastic s...

  Technological developments, such as precision medicine, next-generation sequencing (NGS), and long-read sequencing have made significant advances in science and technology and simultaneously opened avenues for public healthcare. As the next frontier of medicine, the global molecular diagnostics market showcases enormous potential to completely revolutionize patient care and overall wellness in general. The importance of diagnostic tests throughout the entire procedure (i.e., prevention, detection, diagnosis, treatment, and successful management of health conditions) of treating an individual for a particular disease is as consequential as the treatment itself. It has been subjected to extensive research for further refinement of the same. Our healthcare experts have found the  molecular diagnostics market  to be one of the stable markets, and the global market is predicted to grow from $10,914.6 million in 2020 to $24,228.0 million in 2031 and is expected to grow w...